Pathophysiology and Clinical Basis of Prevention and Treatment of Complications of Chronic Liver Disease

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1991 Feb 6

PMID 2013971

Citations 1

Authors

S Wagner

H U Lautz

M J Muller

F W Schmidt

Affiliations

Soon will be listed here.

Abstract

Chronic liver failure is characterized by the appearance of jaundice, ascites, encephalopathy and/or gastrointestinal bleeding. Acute episodes of hepatic decompensation are frequently precipitated by additional events, e.g. septicaemia, diuretic therapy or excessive protein intake. Identification, correction and treatment of these precipitating factors are first steps in the management of chronic liver failure. Nutritional support is important in the treatment of cirrhotic patients, because malnutrition is one of the major determinants of patient outcome. Management of encephalopathy reduces the appearance of gut-derived nitrogenous toxins and corrects imbalances in amino acid metabolism. Treatment of ascites is salt restriction supported by gentle and incremental administration of diuretics. Ursodesoxycholic acid has become a new and promising modality in the management of cholestatic liver diseases. If conservative therapy fails to recompensate liver function, liver transplantation may be indicated.

Citing Articles

Protein-calorie malnutrition in liver cirrhosis.

Lautz H, Selberg O, Korber J, Burger M, Muller M Clin Investig. 1992; 70(6):478-86.

PMID: 1392415 DOI: 10.1007/BF00210228.

References

Nosadini R, Avogaro A, Mollo F, Marescotti C, Tiengo A, Duner E . Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J Clin Endocrinol Metab. 1984; 58(6):1125-32. DOI: 10.1210/jcem-58-6-1125. View

Eriksson L, CONN H . Branched-chain amino acids in the management of hepatic encephalopathy: an analysis of variants. Hepatology. 1989; 10(2):228-46. DOI: 10.1002/hep.1840100218. View

PAPPER S . The role of the kidney in Laennec's cirrhosis of the liver. Medicine (Baltimore). 1958; 37(4):299-316. DOI: 10.1097/00005792-195812000-00002. View

Poupon R, Chretien Y, Poupon R, Ballet F, Calmus Y, DARNIS F . Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet. 1987; 1(8537):834-6. DOI: 10.1016/s0140-6736(87)91610-2. View

Meier R, Gyr K . Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study. Eur J Anaesthesiol Suppl. 1988; 2:139-46. View

Mortensen P, Rasmussen H, Holtug K . Lactulose detoxifies in vitro short-chain fatty acid production in colonic contents induced by blood: implications for hepatic coma. Gastroenterology. 1988; 94(3):750-4. DOI: 10.1016/0016-5085(88)90250-8. View

Giulidori P, Galli-Kienle M, Catto E, Stramentinoli G . Transmethylation, transsulfuration, and aminopropylation reactions of S-adenosyl-L-methionine in vivo. J Biol Chem. 1984; 259(7):4205-11. View

Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J . Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987; 93(2):234-41. DOI: 10.1016/0016-5085(87)91007-9. View

PETRIDES A, DeFronzo R . Glucose metabolism in cirrhosis: a review with some perspectives for the future. Diabetes Metab Rev. 1989; 5(8):691-709. DOI: 10.1002/dmr.5610050805. View

10.

Silk D . Parenteral nutrition in patients with liver disease. J Hepatol. 1988; 7(2):269-77. DOI: 10.1016/s0168-8278(88)80491-4. View

11.

Crossley I, Williams R . Spontaneous bacterial peritonitis. Gut. 1985; 26(4):325-31. PMC: 1432517. DOI: 10.1136/gut.26.4.325. View

12.

Poupon R, Eschwege E, Poupon R . Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol. 1990; 11(1):16-21. DOI: 10.1016/0168-8278(90)90265-s. View

13.

Hiyama D, Fischer J . Nutritional support in hepatic failure: current thought in practice. Nutr Clin Pract. 1988; 3(3):96-105. DOI: 10.1177/011542658800300396. View

14.

Rector Jr W, Hossack K . Pathogenesis of sodium retention complicating cirrhosis: is there room for diminished "effective" arterial blood volume?. Gastroenterology. 1988; 95(6):1658-63. DOI: 10.1016/s0016-5085(88)80092-1. View

15.

Van Leeuwen P, DRUKKER J, Van der Kleyn N, van den Boogaard A, Soeters P . Morphological effects of high dose neomycin sulphate on the small and large intestine. Acta Morphol Neerl Scand. 1986; 24(3):223-34. View

16.

Olsson R . Beta-receptor blocking treatment in portal hypertension. Scand J Gastroenterol. 1990; 25(7):641-6. DOI: 10.3109/00365529008997587. View

17.

Arroyo V, Camps J, Rimola A, Costa J, Gaya J, Rivera F . Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics. Hepatology. 1984; 4(2):247-52. DOI: 10.1002/hep.1840040213. View

18.

Mullen K, Szauter K . "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet. 1990; 336(8707):81-3. DOI: 10.1016/0140-6736(90)91594-z. View

19.

Burke D, Mitchell K, Al Mardini H, Record C . Reversal of hepatic coma with flumazenil with improvement in visual evoked potentials. Lancet. 1988; 2(8609):505-6. DOI: 10.1016/s0140-6736(88)90146-8. View

20.

Skorecki K, Leung W, Campbell P, Warner L, Wong P, Bull S . Role of atrial natriuretic peptide in the natriuretic response to central volume expansion induced by head-out water immersion in sodium-retaining cirrhotic subjects. Am J Med. 1988; 85(3):375-82. DOI: 10.1016/0002-9343(88)90590-6. View